Zimmer Biomet’s (ZBH) “Neutral” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their neutral rating on shares of Zimmer Biomet (NYSE:ZBH) in a research report report published on Monday morning, Marketbeat Ratings reports.

Several other research analysts also recently weighed in on ZBH. UBS Group restated a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Citigroup reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Wells Fargo & Company lifted their target price on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 11th. Barclays cut their price target on Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a research note on Thursday, February 12th. Finally, The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target for the company. in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $87.69 on Monday. The business’s 50-day simple moving average is $91.97 and its 200 day simple moving average is $94.29. The company has a market cap of $17.16 billion, a P/E ratio of 24.77, a PEG ratio of 1.76 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet has a one year low of $84.59 and a one year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same quarter in the prior year, the business earned $2.31 EPS. Zimmer Biomet’s quarterly revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, sell-side analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is currently 27.12%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. The trade was a 20.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.39% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds have recently bought and sold shares of ZBH. Legacy Wealth Asset Management LLC raised its stake in Zimmer Biomet by 2.3% during the third quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after buying an additional 106 shares in the last quarter. Global Retirement Partners LLC increased its holdings in shares of Zimmer Biomet by 7.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 111 shares during the last quarter. Main Management ETF Advisors LLC raised its position in shares of Zimmer Biomet by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after acquiring an additional 112 shares in the last quarter. Cullen Frost Bankers Inc. raised its position in shares of Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Finally, Generali Asset Management SPA SGR lifted its stake in Zimmer Biomet by 0.9% during the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after purchasing an additional 122 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.